The Quigley Corporation (Nasdaq: QGLY) today announced that it had concluded that its patent pending QR-334 formulation for relief of Sialorrhea may qualify for sale as an over-the-counter (OTC) medication. The Company intends to work with associations representing ALS, Parkinson's and other relevant illnesses to develop immediate consumer awareness of this medication and to launch the national rollout of the product as quickly as possible.

"The over-the-counter market may prove to be a more viable approach to bringing the product to the marketplace more quickly and effectively, and could result in a new revenue stream for the Company," said Guy J. Quigley, Chairman, President and Chief Executive Officer of the Company.

Sialorrhea, or excess secretions of the salivary glands, is suffered by approximately 3,000,000 people afflicted by diseases including Amyotrophic Lateral Sclerosis (ALS, commonly known as Lou Gehrig's Disease), Cerebral Palsy, Parkinson's Disease, and Muscular Dystrophy. This condition can cause potentially life-threatening conditions including lung congestion and choking.

Last week, the Company announced that clinical trials of the Company's patented QR-334 Formulation have been arranged under the direction of Dr. Stanley H. Appel, Professor and Chairman of the Department of Neurology at the Baylor College of Medicine, and will commence later this month.

The Quigley Corporation (Nasdaq: QGLY) is a leading developer and marketer of diversified health products including the Cold-Eeze(R) family of patented zinc gluconate glycine (ZIGG(TM)) lozenges, gums and sugar free tablets.